Lakefront Biotherapeutics (LKFT) Change in Accured Expenses (2018 - 2025)
Lakefront Biotherapeutics (LKFT) posted quarterly Change in Accured Expenses of -$176382.9 for Q1 2025, down 109.46% on a QoQ basis from -$84208.6 in Q3 2024.
Lakefront Biotherapeutics (LKFT) Change in Accured Expenses (2018 - 2025) Analysis & Trends
Lakefront Biotherapeutics (LKFT) has reported Change in Accured Expenses for 4 consecutive years, with -$176382.9 the latest figure, recorded in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,102.16 Bn | 67,101.87 Bn | - | 1.13 Mn |
| 2 | Nanobiotix | 1,913.50 Bn | 1,913.44 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | 931,000.00 |
| 4 | BeOne Medicines | 473.74 Bn | 468.95 Bn | 1.35 Bn | -16.82 Mn |
| 5 | Vertex Pharmaceuticals | 122.07 Bn | 114.82 Bn | 2.59 Bn | 23.10 Mn |
| 6 | Regeneron Pharmaceuticals | 70.00 Bn | 61.24 Bn | 3.31 Bn | 107.70 Mn |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - | - |
| 8 | Argenx Se | 55.96 Bn | 50.77 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.49 Bn | 34.48 Bn | 959.66 Mn | -176.03 Mn |
| 10 | Lakefront Biotherapeutics | 1.85 Bn | -1.54 Bn | 1.91 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | -176,382.91 |
| Mar 31, 2025 | -176,382.91 |
| Sep 30, 2024 | -84,208.62 |
| Sep 30, 2024 | -84,208.62 |
| Sep 30, 2019 | -2.20 Mn |
| Sep 30, 2019 | -2.20 Mn |
| Jun 30, 2019 | -2.66 Mn |
| Jun 30, 2019 | -2.66 Mn |
| Mar 31, 2019 | -1.37 Mn |
| Mar 31, 2019 | -1.37 Mn |
| Sep 30, 2018 | -1.17 Mn |
| Sep 30, 2018 | -1.17 Mn |
| Jun 30, 2018 | -551,306.10 |
| Jun 30, 2018 | -551,306.10 |
| Mar 31, 2018 | -490,691.30 |
| Mar 31, 2018 | -490,691.30 |